Omni Health Inc.

Focused on Healthcare, Pharmaceutical and Wellness

/
Volume | Market Cap | Shares | PEG Ratio | EPS

Fundamentals.

Profile:
HQ: Hialeah, Florida
Symbol: OMHE (OTC)
Facilities: pharmacy in Florida

Focus: Weak
Omni Health bought and began operating Malecon Pharmacy, Inc. in June 2016. The Florida pharmacy has been in operation since 1974. It also manufactures, sells, and distributes an anti-aging cream. Omni Health is a subsidiary of LX Retail Group, Inc.

Omni began reformulating its product to include cannabidiol (CBD) and begin its FDA registration for topical pain analgesic.

The company puts out limited news. In late December 20127, it said it is in the final stages of development of non-prescription CBD analgesic creams and ointments with fast absorption properties it would rapidly deploy to the market. They are to be distributed exclusively to doctors’ offices, clinics, and hospitals to ensure appropriate support and usage. They expect to introduce it to North American in Q3 2018. Omni projects generating a recurring annual revenue over $7 million.

Size:
Market Cap: $4.2 million
Employees: 26

Markets:
Florida.  It has a distribution deal in Europe to sell its anti-aging product.

Operations: Neutral
Distribution: N/A
Direct sales: The sells through its single pharmacy in Florida.
Store networks: In December 2017, Omni entered into a distribution agreement with MediCann, a European distributor, for distribution of its anti-aging products in 22 countries in Europe starting March 2018. Europe has a population of 740 million people and good demand for anti-aging and CBD products.

Integration/Diversification: Weak
Vertically integrated: No
Horizontally diversified:  No

Financials: Neutral

Management: Weak*
CEO: Andrey Soloviev
Interim CFO: Andrey Soloviev

*Management does not regular reports and investors are punishing the stock as a result.

Branding: Neutral
The company has an established retail pharmacy, but its poor management is giving it a bad reputation with investors.

Valuation: Strong
Current share price: US$ 0.004
Price to Sales: 1 (Biopharma industry=7.5)
EV / revenue: N/A
EV / revenue rank in industry: N/A

Financings:
No news. Not knowing its financial situation is a serious problem for investors.

Risks: High
The risks of investing in any cannabis company are very high given the newness of the market. The risks of investing in this company are extremely high, since it does not offer regular financial reports nor much of any news about its progress.

Recommendation: Weak
In November 2016, mCig, a diversified cannabis company in Nevada, bought 17 million shares of Omni Health at $0.02 for $100,000. This was a passive investment. So far, they have lost a lot on this deal.

In terms of reporting financials and news, this company is the least responsible of any we have studied to date. It does not send regular financial statements nor much news. After hitting a high of $0.04 last December 2017, it has trended steadily down since and is at $0.004 now. Only investors with extremely high risk tolerance, and a strong knowledge and reliable source of the company’s news, should consider owning this stock.

Get the Q1, ’19 Cannin Report ($99)

Includes the latest market & industry update, 12 technical fundamental analyses, latest regulations by state, new medical research and more!

LEARN MORE

Technicals.

Read Omni Health News